Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACXP NYSE:CPHI NASDAQ:PMN NASDAQ:XCUR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACXPAcurx Pharmaceuticals$2.12+6.0%$3.02$1.33▼$21.00$6.05M-2.092.27 million shs30,411 shsCPHIChina Pharma$0.55-1.1%$0.60$0.50▼$2.60$22.13M0.9942,742 shs1,506 shsPMNPromis Neurosciences$11.08+0.2%$15.74$6.27▼$39.75$99.70M-0.2135,389 shs10,003 shsXCURExicure$3.48+2.4%$3.97$3.10▼$11.86$22.22M3.6227,867 shs4,516 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACXPAcurx Pharmaceuticals-7.41%-2.91%-45.65%-4.76%-74.37%CPHIChina Pharma+1.71%-4.97%-15.08%-25.90%-71.47%PMNPromis Neurosciences+0.45%+1.94%-11.59%-29.33%-30.88%XCURExicure+4.62%-2.02%-18.85%-16.67%-68.31%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACXPAcurx Pharmaceuticals$2.12+6.0%$3.02$1.33▼$21.00$6.05M-2.092.27 million shs30,411 shsCPHIChina Pharma$0.55-1.1%$0.60$0.50▼$2.60$22.13M0.9942,742 shs1,506 shsPMNPromis Neurosciences$11.08+0.2%$15.74$6.27▼$39.75$99.70M-0.2135,389 shs10,003 shsXCURExicure$3.48+2.4%$3.97$3.10▼$11.86$22.22M3.6227,867 shs4,516 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACXPAcurx Pharmaceuticals-7.41%-2.91%-45.65%-4.76%-74.37%CPHIChina Pharma+1.71%-4.97%-15.08%-25.90%-71.47%PMNPromis Neurosciences+0.45%+1.94%-11.59%-29.33%-30.88%XCURExicure+4.62%-2.02%-18.85%-16.67%-68.31%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACXPAcurx Pharmaceuticals 2.00Hold$31.001,362.26% UpsideCPHIChina Pharma 0.00N/AN/AN/APMNPromis Neurosciences 2.50Moderate Buy$42.67285.18% UpsideXCURExicure 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest ACXP, PMN, CPHI, and XCUR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/20/2026ACXPAcurx Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)2/6/2026PMNPromis Neurosciences GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$125.00 ➝ $35.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACXPAcurx PharmaceuticalsN/AN/AN/AN/A$2.07 per shareN/ACPHIChina Pharma$4.14M5.34N/AN/A$0.70 per share0.78PMNPromis NeurosciencesN/AN/AN/AN/A($0.58) per shareN/AXCURExicureN/AN/AN/AN/A$0.62 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACXPAcurx Pharmaceuticals-$7.97M-$5.63N/AN/AN/AN/A-215.54%-128.70%5/12/2026 (Estimated)CPHIChina Pharma-$3.08M-$0.75N/AN/AN/A-85.56%-63.93%-31.42%N/APMNPromis Neurosciences-$39.72M-$19.00N/AN/AN/AN/A-933.63%-295.33%5/11/2026 (Estimated)XCURExicure-$4.95M-$0.77N/AN/AN/AN/A-138.71%-62.76%5/13/2026 (Estimated)Latest ACXP, PMN, CPHI, and XCUR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026N/AXCURExicure-$18.60N/AN/AN/A$1.64 millionN/A5/12/2026Q1 2026ACXPAcurx Pharmaceuticals-$0.59N/AN/AN/AN/AN/A5/11/2026Q1 2026PMNPromis Neurosciences-$1.06N/AN/AN/AN/AN/A3/25/2026Q4 2025XCURExicure-$18.60-$0.46+$18.14-$0.46$1.64 millionN/A3/12/2026Q4 2025ACXPAcurx Pharmaceuticals-$1.01-$0.31+$0.70-$0.31N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthACXPAcurx PharmaceuticalsN/AN/AN/AN/AN/ACPHIChina PharmaN/AN/AN/AN/AN/APMNPromis NeurosciencesN/AN/AN/AN/AN/AXCURExicureN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACXPAcurx PharmaceuticalsN/A3.183.18CPHIChina Pharma0.220.790.26PMNPromis NeurosciencesN/A0.880.88XCURExicureN/A1.191.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACXPAcurx Pharmaceuticals11.53%CPHIChina PharmaN/APMNPromis Neurosciences50.13%XCURExicure42.82%Insider OwnershipCompanyInsider OwnershipACXPAcurx Pharmaceuticals20.30%CPHIChina Pharma6.40%PMNPromis Neurosciences1.50%XCURExicure52.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACXPAcurx Pharmaceuticals32.86 million2.28 millionNo DataCPHIChina Pharma25040.52 million15.92 millionNot OptionablePMNPromis Neurosciences58.97 million8.83 millionNot OptionableXCURExicure506.37 million3.01 millionNot OptionableACXP, PMN, CPHI, and XCUR HeadlinesRecent News About These CompaniesExicure, Inc. and Adbiotech Co., Ltd. Announce Co-Development Agreement for Burixafor Combination TherapiesApril 22, 2026 | quiverquant.comQExicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)April 22, 2026 | globenewswire.comExicure Inc.April 13, 2026 | barrons.comExicure Strengthens Leadership With New COO and DirectorApril 10, 2026 | tipranks.comSummary Notice of Pendency and Proposed Settlement of Stockholder Derivative ActionsApril 2, 2026 | globenewswire.comExicure, Inc. Reports 2025 Financial Results and Announces Need for Additional FinancingMarch 25, 2026 | quiverquant.comQExicure, Inc. Reports 2025 Financial Results and Highlights Need for Additional FinancingMarch 25, 2026 | quiverquant.comQExicure, Inc. Reports Full Year 2025 Financial ResultsMarch 25, 2026 | globenewswire.comExicure, Inc. Reports Full Year 2025 Financial ResultsMarch 25, 2026 | globenewswire.comExicure, Inc. Publishes Phase 2 Study Results for Burixafor, a Novel CXCR4 Inhibitor in Hematologic Disease TreatmentFebruary 5, 2026 | quiverquant.comQExicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing TransplantFebruary 5, 2026 | globenewswire.comExicure, Inc. to Present Phase 2 Trial Results for Burixafor at 2026 ASTCT and CIBMTR Tandem MeetingsJanuary 21, 2026 | quiverquant.comQExicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem MeetingsJanuary 21, 2026 | globenewswire.comSangsangin Investment & Securi Sells 433,332 Shares of Exicure (NASDAQ:XCUR) StockDecember 11, 2025 | insidertrades.comFutures tread cautiously pre-market as investors await key Fed decision: NVDA, XCUR, GME, CASY among stocks to watchDecember 10, 2025 | msn.comThis BlackRock stock just rocketed 70%December 9, 2025 | finbold.comFExicure presents topline data from burixafor combination trialDecember 8, 2025 | msn.comExicure stock soars after positive Phase 2 data for multiple myeloma drugDecember 8, 2025 | investing.comExicure, Inc. Reports Positive Phase 2 Trial Results for Burixafor in Hematopoietic Progenitor Cell Mobilization in Multiple Myeloma PatientsDecember 8, 2025 | quiverquant.comQExicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual MeetingDecember 8, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACXP, PMN, CPHI, and XCUR Company DescriptionsAcurx Pharmaceuticals NASDAQ:ACXP$2.12 +0.12 (+6.00%) As of 11:20 AM Eastern This is a fair market value price provided by Massive. Learn more.Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.China Pharma NYSE:CPHI$0.55 -0.01 (-1.12%) As of 11:12 AM Eastern This is a fair market value price provided by Massive. Learn more.China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.Promis Neurosciences NASDAQ:PMN$11.08 +0.02 (+0.15%) As of 11:20 AM Eastern This is a fair market value price provided by Massive. Learn more.ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.Exicure NASDAQ:XCUR$3.48 +0.08 (+2.35%) As of 11:20 AM Eastern This is a fair market value price provided by Massive. Learn more.Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
